1213093-30-1

Usage

Uses

Used in Pharmaceutical Industry:
(R)-5-fluoro-2-methoxy-3-(pyrrolidin-2-yl)pyridine is used as a selective Trk kinase inhibitor for its potential role in the development of targeted therapies for various diseases. Trk kinases are a family of receptor tyrosine kinases that play a crucial role in cell growth, survival, and differentiation. Inhibition of these kinases can be beneficial in treating conditions where uncontrolled cell growth or survival is a concern, such as cancer.
The compound's selectivity for Trk kinases makes it a promising candidate for the development of drugs with fewer off-target effects, which can lead to improved safety and efficacy profiles. Further research and development are necessary to fully understand the potential applications and limitations of (R)-5-fluoro-2-methoxy-3-(pyrrolidin-2-yl)pyridine in the pharmaceutical industry.

Upstream product

• 884494-81-9 3-bromo-5-fluoro-2-methoxypyridine 
• 351410-62-3 5-fluoro-2-methoxypyridine-3-carbaldehyde 

Downstream Products

• 2097002-61-2 (1³E,1⁴E,2²R,6R)-3⁵-fluoro-6-methyl-7-aza-1(5,3)-pyrazolo[1,5-a]pyrimidina-3(3,2)-pyridina-2(1,2)-pyrrolidinacyclooctaphan-8-one 

Relevant academic research and scientific papers

Macrocyclic compound, and preparation method and application thereof

The invention discloses a macrocyclic kinase inhibitor, and a compound, or a stereoisomer or a pharmaceutically acceptable salt thereof as shown in a formula (I). Experiments show that the novel compound shown in the formula (I) shows good TRK inhibitory

TROPOMYOSIN RECEPTOR KINASE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF

Disclosed in the present invention are a pyrazolo [1,5-a]pyrimidine derivative having a structure of formula (I), a pharmaceutical composition comprising the compound of formula (I), and use of the compound in the preparation of a medicament for preventing or treating diseases associated with tropomyosin receptor kinases, in particular for preventing or treating cancers associated with tropomyosin receptor kinases. Each substituent in formula (I) has the same definition as that in the description.

Pyrazolopyrimidine macrocyclic derivative and application thereof

The invention relates to a novel pyrazolopyrimidine macrocyclic derivative as well as a preparation method and application thereof in medicines. Specifically, the invention relates to a new pyrazolopyrimidine macrocyclic derivative as shown in a general formula (I), a preparation method thereof, and application of the pyrazolopyrimidine macrocyclic derivative or a pharmaceutical composition containing the derivative as a therapeutic agent, especially as a tropomyosin-related kinase (TRK) inhibitor, in treatment or prevention of TRK-mediated related diseases such as tumors. Substituents (R1, R2) and groups (X) in the general formula (I) are as defined in the description.

Heterocyclic compound as TRK inhibitor

The present invention relates to a compounds, a pharmaceutical compositions containing the compound, preparation methods of the compound and the pharmaceutical composition, and uses of the compound and the pharmaceutical composition as TRK inhibitors, wherein the compound is a compound represented by a formula I, or a pharmaceutically acceptable salt, a prodrug, a solvent compound, a polymorph, anisomer and a stable isotope derivative thereof. The invention further relates to uses of the compound in treatment or prevention of TRK-mediated related diseases such as tumors, and a method for treating the diseases by using the compound.

FORMULATIONS OF A MACROCYCLIC TRK KINASE INHIBITOR

The present application in some embodiments provides a pharmaceutical composition comprising Compound (1), and a compounding agent. Further provided herein are methods of making and methods of using the pharmaceutical compositions, for example, in the treatment of cancer.

PROCESS FOR THE PREPARATION OF PYRAZOLO[1,5-a]PYRIMIDINES AND SALTS THEREOF

In some embodiments, provided herein are processes for preparing a compound of Formula C or a salt thereof, as disclosed herein. In some embodiments, provided herein is a compound of Formula I or a pharmaceutically acceptable salt, solvate or hydrate thereof. In some embodiments, provided herein is a solid form of the compound, such as a crystalline form of the compound crystalline Form I.

SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS

Compounds of Formula (I) and salts thereof in which R1, R2, R3, R4, X, Y and n have the meanings given in the specification, are inhibitors of Trk kinases and are useful in the treatment of diseases which can be treated with a Trk kinase inhibitor such as pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.